Supplementary tables 5-17 - Data tables generated during RNA-seq and ChIP-seq analysis, and the information on the siRNA screens. from BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation

<p>Table S5. The list of genes significantly altered in H446 cells after NEUROD1 KO. Table S6. The list of NEUROD1 peaks identified in H446 control cells (control gRNA, cl.10) Table S7. The list of NEUROD1 target genes identified by BETA. Table S8. Gene Descriptions Table S9. The list of genomic regions singly occupied by BRD4 in H446 control cells (control gRNA cl. 10). Table S10. The list of genes with significantly altered expression after JQ1 treatment (24 hrs, 1µM) in H446 control cells (control gRNA cl.10). Table S11. The list of genes with significantly altered expression after JQ1 treatment (24 hrs, 1µM) in H446 NEUROD1-KO cells (#297 cl.2-1). Table S12. The list of genes with significantly altered expression after JQ1 treatment (24 hours at 0.5µM) in COR-L279 cells. Table S13. The list of NEUROD1-loaded superenhancers in H446 control cells (control gRNA cl.10). Table S14. The list of BRD4-loaded superenhancers in H446 control cells (control gRNA cl.10). Table S15. The list of BRD4-loaded superenhancers in H446 NEUROD1-KO cells (#297 cl.2-1). Table S16. Information on the Qiagen custom siRNA library. Table S17. The list of genes with significantly altered expression in SCLC PDX LX22 following 5-day NHWD-870 treatment (3mg/kg via gavage daily; n=6 /group).</p>

Duke Scholars

Author Trudy G Oliver Pharmacology & Cancer Biology